{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T18:31:12Z","timestamp":1772130672583,"version":"3.50.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81804136"],"award-info":[{"award-number":["81804136"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Backgrounds:<\/jats:title>\n            <jats:p>Polycystic ovary syndrome (PCOS) constitutes an endocrine and metabolic disorder characterized by hyperandrogenemia, ovulation disorders, and polycystic ovary. Existing therapy is low efficacy and has significant side effects. In traditional Chinese medicine, tanshinone was used for PCOS women. Here, we will investigate the safety, as well as the efficacy of tanshinone in treating polycystic ovary syndrome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Two researchers will independently research eligible randomized controlled trials in 6 repositories: PubMed, CINAHL, Web of Science, EMBASE, China National Knowledge Infrastructure (CNKI), as well as Cochrane Library, from their onset to present. The languages will constitute either English or Chinese, and we will carry out article selection, data mining, and conduct an evaluation of the risk of bias by the Cochrane tool of risk of bias. All analyses will be conducted by using the Cochrane Review Manager software (RevMan 5.3).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results and conclusion:<\/jats:title>\n            <jats:p>This study will provide the latest research evidence on the efficacy, as well as safety of tanshinone for PCOS patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Registration number:<\/jats:title>\n            <jats:p>INPLASY2020100017<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000024287","type":"journal-article","created":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T13:42:15Z","timestamp":1611409335000},"page":"e24287","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Tanshinone for polycystic ovary syndrome"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7936-3557","authenticated-orcid":false,"given":"Yijiao","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiani","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honglin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaorong","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"R1-20250504","first-page":"661","article-title":"Polycystic ovarian syndrome: clinical and biological diagnosis","volume":"74","author":"Bachelot","year":"2016","journal-title":"Ann Biol Clin (Paris)"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1093\/humrep\/dew218","article-title":"The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis","volume":"31","author":"Bozdag","year":"2016","journal-title":"Hum Reprod"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/NMC.0b013e31824239ce","article-title":"Treating polycystic ovary syndrome and infertility","volume":"37","author":"McFarland","year":"2012","journal-title":"MCN Am J Matern Child Nurs"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.metabol.2017.09.016","article-title":"Polycystic ovarian syndrome (PCOS): long-term metabolic consequences","volume":"86","author":"Anagnostis","year":"2018","journal-title":"Metabolism"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.cca.2019.11.003","article-title":"Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity","volume":"502","author":"Zeng","year":"2020","journal-title":"Clin Chim Acta"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.3390\/ijms21134753","article-title":"Lipidomic biomarkers in polycystic ovary syndrome and endometrial cancer","volume":"21","author":"Shafiee","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"e4863","DOI":"10.1097\/MD.0000000000004863","article-title":"Association between polycystic ovary syndrome and the risk of pregnancy complications: a PRISMA-compliant systematic review and meta-analysis","volume":"95","author":"Yu","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1179558119871467","DOI":"10.1177\/1179558119871467","article-title":"The source of polycystic ovarian syndrome","volume":"13","author":"Raperport","year":"2019","journal-title":"Clin Med Insights Reprod Health"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nrendo.2018.24","article-title":"Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment","volume":"14","author":"Escobar-Morreale","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.4158\/EP15748.DSCPT2","article-title":"American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and Pcos Society Disease State Clinical Review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - part 2","volume":"21","author":"Goodman","year":"2015","journal-title":"Endocr Pract"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1007\/s00125-017-4306-3","article-title":"Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome","volume":"60","author":"Sam","year":"2017","journal-title":"Diabetologia"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMoa063971","article-title":"Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome","volume":"356","author":"Legro","year":"2007","journal-title":"N Engl J Med"},{"key":"R13-20250504","first-page":"785","article-title":"Metformin for the treatment of polycystic ovary syndrome","volume":"101","author":"Barbieri","year":"2003","journal-title":"Obstet Gynecol"},{"key":"R14-20250504","first-page":"CD010931","article-title":"Risk of endometrial cancer in women treated with ovary-stimulating drugs for subfertility","volume":"3","author":"Skalkidou","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.biopha.2017.06.040","article-title":"Tanshinone I alleviates insulin resistance in type 2 diabetes mellitus rats through IRS-1 pathway","volume":"93","author":"Wei","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"e003646","DOI":"10.1136\/bmjopen-2013-003646","article-title":"Effects of tanshinone on hyperandrogenism and the quality of life in women with polycystic ovary syndrome: protocol of a double-blind, placebo-controlled, randomised trial","volume":"3","author":"Shen","year":"2013","journal-title":"BMJ Open"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"e12716","DOI":"10.1111\/dth.12716","article-title":"The therapeutic effect of tanshinone IIA on Propionibacterium acnes-induced inflammation in vitro","volume":"31","author":"Li","year":"2018","journal-title":"Dermatol Ther"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.abb.2016.01.001","article-title":"Tanshinone IIA affects the HDL subfractions distribution not serum lipid levels: involving in intake and efflux of cholesterol","volume":"592","author":"Jia","year":"2016","journal-title":"Arch Biochem Biophys"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"152871","DOI":"10.1016\/j.phymed.2019.152871","article-title":"Salvia miltiorrhiza in diabetes: a review of its pharmacology, phytochemistry, and safety","volume":"58","author":"Jia","year":"2019","journal-title":"Phytomedicine"},{"key":"R20-20250504","first-page":"630","volume":"30","author":"Chen","year":"2005","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1208\/s12248-014-9666-8","article-title":"Blocking of JB6 cell transformation by tanshinone IIA: epigenetic reactivation of Nrf2 antioxidative stress pathway","volume":"16","author":"Wang","year":"2014","journal-title":"AAPS J"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation [published correction appears in BMJ. 2016 Jul 21;354:i4086]","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-0038-1668085","article-title":"A summary on polycystic ovary syndrome: diagnostic criteria, prevalence, clinical manifestations, and management according to the latest international guidelines","volume":"36","author":"Neven","year":"2018","journal-title":"Semin Reprod Med"},{"key":"R24-20250504","first-page":"777","article-title":"Early impaired \u03b2-cell function in chinese women with polycystic ovary syndrome","volume":"5","author":"Tao","year":"2012","journal-title":"Int J Clin Exp Pathol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T07:00:47Z","timestamp":1746342047000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024287"}},"subtitle":["A protocol of systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000024287","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,22]]},"assertion":[{"value":"2020-12-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}